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Abstract
Background: C-reactive protein is an acute-phase 
proteins, produce in the liver, its release is stimulated by 
cytokines (interleukin 6 and tumour necrosis factor alpha). 
Elevated level of it is a risk factor for coronary heart 
disease. Baseline levels of C-reactive protein in 
apparently healthy men and women predict long-term risk 
of a first myocardial infarction. Diabetics are at increased 
risk for coronary heart disease, data from the 
Framingham Study showed a two-to three-fold elevation 
in the risk of clinically evident atherosclerotic disease in 
patients with type II diabetes compared to those without 
diabetes. However, but data regarding CRP in Nigerian 
diabetic is lacking.
Method: A cross-sectional study conducted among 
patients attending out patient clinic of the Obafemi 
Awolowo University Teaching Hospitals complex 
(OAUTHC) Ile Ife, Osun State south western Nigeria. 
Measurement of C-reactive protein was based on the 
principle of solid phase enzyme-linked immunosorbent 
assay (ELISA).
Results: A total of 125 consecutive subjects were 
recruited comprising 75 patients with type II diabetes 
mellitus with or without hypertension and 50 apparently 
healthy age-and-sex comparable controls. There was a 
significant difference between the mean systolic and 
diastolic blood pressures of the patients and controls. The 
fasting blood glucose and C-reactive protein were 
significantly higher in diabetics compared to controls. 
There was a positive and significant correlation between 
FBG and CRP in both patients and controls.
Conclusion: This study showed that diabetics have 
significantly higher serum C-reactive protein compared to 
the apparently controls. Also there was a positive and 
significant correlation between C-reactive protein and 
fasting blood glucose among both patients and controls.
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Introduction
C- reactive protein was first identified by Tilet and 
Francis in1930 in the plasma of patients with 
pneumonia and was named for its ability to bind and 
precipitate the capsular polysaccharide of 
1
pneumococcus.  It is synthesized in the liver and is 
normally present as a trace constituent of serum or 
2
plasma at levels less than 0.25-1.5µg/ml.  Studies have 
shown  that elevated levels of CRP is a risk factor for 
4-6coronary heart disease (CHD).  Baseline levels of CRP 
in apparently healthy men and women predict long-term 
5
risk of a first myocardial infarction.  In older men and 
women, elevated CRP was found to be associated with 
a 10-year risk of CHD regardless of the presence or 
6
absence of cardiac risk factors.  A single CRP 
measurement provides information beyond 
conventional risk assessment, especially in the 
intermediate Framingham risk men and high 
6Framingham risk women.  Elevated CRP levels have 
also been linked to an increased risk of later 
7
development of diabetes mellitus.
Diabetics are at increased risk for CHD, data from the 
Framingham Study showed a two-to three-fold 
elevation in the risk of clinically evident atherosclerotic 
disease in patients with type II diabetes compared to 
8
those without diabetes.  Diabetic men in the Multiple 
Risk Factor Intervention Trial (MRFIT) study had an 
absolute risk of CHD death more than three times higher 
than that in the non-diabetic cohort, even after 
9 
adjustment for established risk factors. National 
cholesterol education program considers diabetes 
10
mellitus to be a CHD equivalent in their lipid guideline.  
Diabetic patients with no history of CHD have the same 
risk for future myocardial infarction as do non-diabetic 
11patients with known CHD.  Diabetes eliminates the 
usual female advantage in the risk of death from CHD, 
as these patients have a 5-8 fold higher death rate than 
1 2do non-diabetic women.  Several proposed 
pathophysiologic mechanisms are implicated in the 
pathogenesis of vascular disease in diabetes mellitus. 
These include endothelial dysfunction, diabetic 
428
dyslipidaemia, hypercoagulability, impaired fibrinolysis, 
platelet hyperaggregability, oxidative stress and toxic 
13effects of hyperglycaemia.
However study regarding C-reactive protein in Nigerian 
diabetics is lacking hence decision to carry out this study 
to find out the relationship between C-reactive and 
diabetes mellitus in our population.
Materials and Methods
The study design was cross-sectional conducted among 
patients attending out patient clinic of the Obafemi 
Awolowo University Teaching Hospitals complex 
(OAUTHC) Ile Ife, Osun State south western Nigeria. It 
comprised 75 consecutive patients with type II diabetes 
mellitus with or without hypertension and 50 apparently 
healthy age- and sex- comparable controls from the 
hospital staff and patient relatives who are themselves not 
relatives of the study patients were recruited. Using a 
structured pre-evaluated questionnaire, the demographic 
data, history of cigarette smoking, alcohol consumption, 
duration of diabetes, duration of hypertension were 
explored. 
The diagnosis of diabetes mellitus was made on the basis 
of the reported history and medical records. Diabetic with 
chronic kidney disease, chronic liver disease, congestive 
cardiac failure or systemic infection were excluded from 
the study. Also excluded from the study were diabetics on 
oral contraceptive pills, analgesics or anti-inflammatory 
drugs and those on HMGcoA reductase inhibitor (statins). 
Diabetics aged less than eighteen years and those that 
did not consent were also excluded from the study. Ethical 
clearance was obtained from the ethics and research 
Committee of the Obafemi Awolowo University Teaching 
Hospitals Complex, and all participating subjects signed 
the informed consent form after being clearly explained to 
them. The following investigations were carried out: 
Fasting blood glucose and 2-hour post prandial, fasting 
lipid, serum electrolytes, urea and creatinine. Urinalysis 
was done using dip-stick while measurement of C-
reactive protein was based on the principle of solid phase 
enzyme-linked immunosorbent assay (ELISA).
Data Analysis
Data was presented as mean � standard 
deviation (SD). Student t-test was used to test 
the significance of differences between mean 
values of continuous variables and Spearman's 
correlation coefficient was performed to 
determine the association between variables. 
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With statistical significance set at p 
(probability) value less than 0.05. Tables and 
figures were used to present data, Statistical 
Package for Social Sciences version 11.0 
(SPSS Chicago Ill. USA) was used for all 
statistical analysis. 
Results
Demographic and clinical characteristics of the 
study population
A total of 125 consecutive subjects were recruited 
comprising 75 patients with type II diabetes mellitus 
with or without hypertension and 50 apparently healthy 
age-and-sex comparable controls. Forty-five (60.0%) 
patients and 31 (62.0%) controls were females with 
mean ages ± SD of 57.2 ± 9.4 years and 56.6 ± 7.8 
years, respectively (p = 0.804). Thirty (40.0%) patients 
and 19 (38.0%) controls were male with mean ages of 
58.3 ± 10.3 years and 58.3 ± 7.3 years, respectively (p 
= 0.995). 
Body mass index differed significantly between patients 
and controls. The mean BMI of the patients and controls 
2 2were 26.0±5.1 kg/m  and 21.9±1.6 kg/m , respectively 
(p = 0.000). Thirty (40.0%) patients and 48 (96.0%) 
2controls had normal BMI (18.5-24.9 kg/m ) (Fishers 
exact test, p = 0.000), 27 (36.0%) patients and 2 (4.0%) 
2
controls were overweight (BMI = 25-29.9 kg/m ) 
(Fishers exact test, p = 0.000); while, 12 (15.0%) 
2patients were obese (BMI = 30 kg/m ) and the remaining 
2
6 (8.0%) were underweight (BMI < 18.5kg/m ). The 
mean waist circumference of the female patients and 
controls were 92.5 ± 10.0 cm and 81.5 ± 2.7 cm, 
respectively (p = 0.000). While male patients and 
controls had a mean waist circumference of 95.3 ± 7.2 
cm and 92.8 ± 2.4 cm, respectively (p = 0.162). 
Fifty-two (69.3%) patients were hypertensive-diabetic 
and 23 (30.7%) were normotensive-diabetic. Thirty-four 
(65.38%) out of the 52 hypertensive-diabetic were 
females, while the remaining 18 (34.61%) were males, 
while 50 (100%) controls were apparently healthy 
subjects. The mean systolic blood pressure of the 
patients and controls were 144.0 ± 12.2 mmHg and 
120.2 ± 9.1 mmHg, respectively (p = 0.000),while the 
mean diastolic blood pressure were 87.1 ± 8.0 mmHg 
and 79.8 ± 8.2 mmHg, respectively (p = 0.000). 
Laboratory parameters of the study population
 The mean fasting blood glucose of the patients was 9.3 
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± 2.4 mmol/L and was significantly higher than that of the 
controls 4.5 ± 1.0 mmol/L (p = 0.000). Patients had 
significantly higher than controls 2.5 ± 0.5 µg/mL and 1.5 
± 0.4 µg/mL, respectively (p = 0.000). The mean serum 
total cholesterol of the patients and controls were 5.7 ± 
1.3 mmol/L and 3.9 ± 1.2 mmol/L, respectively (p = 
0.000). While the serum LDL cholesterol of the patients 
and controls were 4.0 ± 0.7 mmol/L and 2.1 ± 0.4 mmol/L, 
respectively (p = 0.000). There was a significant 
difference in the mean serum triglycerides between 
patients and controls 2.3 ± 0.5 mmol/L and 1.4 ± 0.2 
mmol/L, respectively.(p = 0.000). Serum HDL cholesterol 
was significantly lower in patients compared to controls 
0.9 ± 0.2 mmol/L and 1.78 ± 0.2 mmol/L, respectively. (p = 
0.000).
There was a positive and significant correlation between 
FBG and CRP in both patients and controls (r = 0.656, p = 
0.000) and (r = 0.551, (p= 0.000) respectively. Similar 
correlations were also observed between CRP and BMI, 
CRP and systolic blood pressure, CRP and diastolic 
blood pressure in both  patients and controls (r = 0.942, p 
= 0.000) and ( r = 0.893, p = 0.000), (r = 0.667, p = 0.000) 
and (r = 0.738, p = 0.000), (r = 0.438, p = 0.000) and ( r = 
0.686, p = 0.000), respectively. However, there was no 
significant correlation between the durations of 
hypertension and diabetes with CRP among the study 
patients (r = 0.135, p = 0.251) and (r = 0.039, p = 0.739) 
respectively.
On regression analysis, BMI, systolic blood pressure, 
diastolic blood pressure and FBG were significantly 
associated with CRP among patients (beta value 0.642, p 
= 0.000), (beta value 0.409, p = 0.001), (beta = 0.162, p = 
0.032) and (beta = 0.119, p = 0.036), respectively. 
Similarly, in the control group, BMI, systolic blood 
pressure, diastolic blood pressure, and FBG were 
significantly associated with CRP, (beta = 0.765, p = 
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Table II Laboratory parameters of the study population.
Parameters Patients Controls p-value
FBG (mmol/L) 9.3±2.4 4.5±1.0 0.000*
CRP (µg/mL) 2.5±0.5 1.5±0.4 0.000*
Total cholesterol  5.7±1.3 3.9±1.2 0.000*
(mmol/L)
LDL cholesterol 4.0±0.7 2.1±0.4 0.000*
(mmol/L
HDL cholesterol 0.9±0.2 1.8±0.2 0.000*
(mmol/L)
Triglycerides 2.3±0.5 1.4±0.2 0.000*
(Mmol/L)
Serum sodium 134.6±3.2 137.1±3.5 0.000*
(mmol/L)
Serum potassium 3.9±4.2 4.1±4.9 0.793
(mmol/L)
Serum bicarbonate 22.8±2.7 24.5±2.4 0.000*
(mmol/L)
Serum urea 5.3±6.6 3.6±0.6 0.075 
(mmol/L)
Serum creatinine 90.6±37.5 58.2±8.5 0.000*
FBG = Fasting Blood Glucose, CRP = C - reactive protein, LDL = Low Density 
Lipoprotein, HDL = High Density Lipoprotein, GFR = Glomerular Filtration Rate, * 
= Significant at p < 0.05 
Table I: Demographic and social characteristics of the study 
population.
Parameters Patients Controls P-Value
Age
Male 58.3±10.3 58.3±7.3 0.995
Female 57.2±9.4 56.6±7.8 0.804
Sex
Male 30(40.0%) 19(38.0%) 0.822
Female 45(60.0%) 31(62.0%) 0.822
2BMI (kg/m ) 26.0±5.1 21.9±1.6 0.000*
<18.5 6 (8.0%) 0 (0.0%) 0.080
18.5-24.9 30 (40.0%) 48 (96.0%) 0.000*
25-29.9 27 (36.0%) 2 (4.0%) 0.000*
30-34.9 8 (10.7%) 0 (0.0%) 0.021*
35-39.9 3 (4.0%) 0 (0.0%) 0.274
>40 1 (1.3%) 0 (0.0%) 1.000
Waist circum-ference (cm)
Male 95.3±7.2 92.8±2.48 0.162
Female 92.5±1.0 81.5±2.7 0.000*
SBP (mmHg) 144.0±12.2 120.2±9.1 0.000*
DBP (mmHg) 87.1±8.0 79.8±8.2 0.000*
BMI = Body Mass Index, DBP = Diastolic Blood Pressure, 
SBP = Systolic Blood Pressure
Table II Comparison of CRP levels between hypertensive- 
diabetic and normotensive-diabetic
_________________________________________________________
Parameter Hypertensive-diabetic Normotensive-diabetic P-value
N=52 N=23
_________________________________________________________
CRP 2.51±0.53 2.54±0.44 0.823
_________________________________________________________
CRP = C - reactive protein
Table IV Correlation between CRP and systolic blood pressure, diastolic 
blood pressure, body mass index and fasting blood glucose in the study 
patients.
Parameters Spearman correlation Coefficient (r)      P-value
SBP (mmHg) 0.667      0.000*
DBP (mmHg) 0.438        0.000*
2BMI (kg/m ) 0.942      0.000*
FBG (mmol/L) 0.656      0.000*
BMI = Body Mass Index, DBP = Diastolic Blood Pressure, SBP = Systolic Blood 
Pressure, FBG = Fasting Blood Glucose
Table V Correlation between CRP and systolic blood pressure, diastolic blood 
pressure body mass index and fasting blood glucose among controls.
Parameters Spearman correlation coefficient (r)      P-value
SBP (mmHg) 0.738         0.000*
DBP (mmHg) 0.686         0.000*
2BMI (kg/m ) 0.893         0.000*
FBG (mmol/L) 0.551         0.000*
BMI = Body Mass Index, DBP = Diastolic Blood Pressure, SBP = Systolic Blood 
Pressure, FBG = Fasting Blood Glucose
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Table VI Correlation between CRP and duration of hypertension and diabetes 
in the study patients
Parameters          Spearman correlation coefficient (r) P Value
Duration of hypertension         0.135 0.251
Duration of diabetes          0.039 0.739
Table VII Multiple regression analysis between CRP and body mass index, 
systolic blood pressure, diastolic blood pressure and fasting blood glucose 
among study patients.
Parameters Beta value P-value
2BMI (kg/m ) 0.642 0.000*
SBP (mmHg) 0.409 0.000*
DBP (mmHg) 0.162 0.032*
FBG (mmol/L) 0.119 0.036*
BMI = Body Mass Index, DBP = Diastolic Blood Pressure, SBP = Systolic Blood 
Pressure, FBG = Fasting Blood Glucose
Table VIII Multiple regression analysis between CRP and body mass index, 
systolic blood pressure, diastolic blood pressure and fasting blood glucose 
among controls.
Parameters Beta value P-value
2BMI (kg/m ) 0.602 0.000*
SBP (mmHg) 0.765 0.001*
DBP (mmHg) 0.689 0.001*
FBG (mmol/L) 0.375 0.000*
BMI = Body Mass Index, DBP = Diastolic Blood Pressure, SBP = Systolic Blood 
Pressure, FBG = Fasting Blood Glucose
Fig 1 Graphical presentation of correlation between CRP and 
FBG among patients
Fig 2 Graphical presentation of correlation between CRP and 
FBG among controls CRP = C-Reactive Protein, FBG = Fasting 
Blood Glucose
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Discussion
This cross-sectional study of CRP in Nigerians with type 
II diabetes mellitus with or without hypertension showed 
that CRP levels are significantly higher in diabetic than 
controls. Similarly, there was a positive and significant 
14 
correlation between CRP levels and FBG. Ford had 
previously reported a similar result, though in his study 
he used glycated haemoglobin to determine the level of 
glycaemic control in those with diabetes. This study is 
limited by lack of facilities to test for glycated 
haemoglobin. The pathophysiologic mechanisms for 
the elevated CRP in diabetic is linked to the toxic effects 
of hyperglycaemia on vascular endothelium, increased 
oxidative stress and the associated generation of free 
radicals which is injurious to vascular endothelium and 
triggers inflammation and cytokines release (interleukin 
6, tumour necrosis factor alpha). These cytokines in turn 
stimulate the synthesis and release of CRP from the 
15 and 16liver.
The study also showed a positive and significant 
correlation between CRP and systolic, as well as 
diastolic blood pressure. However, there was no 
significant difference in the serum CRP levels between 
hypertensive-diabetic and normotensive-diabetic. This 
result is consistent with what was previously reported by 
17,18 
other workers.  Similarly, there was no significant 
correlation between the duration of hypertension and 
diabetes with CRP among the study patients. This 
suggests that good glycaemic and blood pressure 
control are associated with lower serum CRP levels 
than the absolute duration of hypertension or diabetes. 
The link between hypertension and CRP was thought to 
be mediated via angiotensin II. Angiotensin II has, in 
addition to potent vasoconstricting effect, a 
proinflammatory effect and CRP has been found to up 
regulate angiotensin I receptor mRNA and increase the 
number of angiotensin I receptor binding sites in 
vascular smooth muscle cells. Angiotensin I receptor is 
a key atherosclerotic switch facilitating angiotensin-II-
induced reactive oxygen species production, vascular 
smooth muscle cell migration, proliferation, and 
19vascular remodelling.
Lipid abnormalities occur frequently in diabetic, and in 
this study it was observed that HDL cholesterol level 
was significantly lower in patients compared to controls. 
On the other hand, serum total cholesterol, triglycerides 
and LDL cholesterol levels were significantly higher in 
patients compared to controls, this result is similar to 
20what was reported by Bruno et al.  The underlying 
pathogenesis and the interrelationships between 
diabetes mellitus and lipid abnormalities have not been 
431
completely elucidated. However, insulin resistance has 
been hypothesized to be the common underlying 
21pathogenic mechanism.
Conclusion
This study showed that diabetics have significantly 
higher serum C-reactive protein compared to the 
apparently controls. Also there was a positive and 
significant correlation between C-reactive protein and 
fasting blood glucose among both patients and controls.
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